Candel Therapeutics financials
$10.88−2.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $125.0K | $125.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $125.0K | $125.0K |
| Gross margin | — | — | — | 100.0% | 100.0% |
| Operating income | -$48.3M | -$33.4M | -$38.4M | -$34.7M | -$25.7M |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M | -$36.1M |
| Net margin | — | — | — | −15035.2% | −28899.2% |
| Diluted EPS | $-0.72 | $-1.74 | $-1.31 | $-0.65 | $-1.91 |
| EBITDA | -$47.4M | -$32.4M | -$37.4M | -$33.9M | -$25.5M |
| Operating cash flow | -$38.3M | -$27.0M | -$34.2M | -$31.4M | -$22.2M |
| Free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M | -$24.1M |
| Diluted shares | 53.0M | 31.7M | 28.9M | 28.8M | 18.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $119.7M | $102.7M | $35.4M | $70.1M | $82.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $47.1M | $12.5M | $21.3M | $20.9M | $560.0K |
| Total assets | $125.2M | $106.9M | $41.2M | $77.7M | $89.2M |
| Total liabilities | $73.3M | $40.5M | $28.5M | $30.0M | $25.1M |
| Shareholders' equity | $51.9M | $66.3M | $12.7M | $47.7M | $64.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology